Imatinib versus newer generation <scp>TKIs</scp> for upfront therapy in chronic phase <scp>chronic myeloid leukemia</scp>: What is the rationale for paying more to get the same survival benefit?

Authors: Jeffrey H. Lipton

Published: 2024-08-14

DOI: HTTPS://DOI.ORG/10.1002/ajh.27455

Keywords: No keywords found.

Abstract:
No abstract found.

Source: